The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Abstract
Purpose: Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated the prespecified hypothesis that the presence of a lymphocytic infiltrate in cancer tissue predicts the response to neoadjuvant chemotherapy. Methods: We investigated intratumoral and stromal lymphocytes in a total of 1,058 pretherapeutic breast cancer core biopsies from two neoadjuvant anthracycline/taxane-based studies (GeparDuo, n = 218, training cohort; and GeparTrio, n = 840, validation cohort). Molecular parameters of lymphocyte recruitment and activation were evaluated by kinetic polymerase chain reaction in 134 formalin-fixed, paraffin-embedded tumor samples. Results: In a multivariate regression analysis including all known predictive clinicopathologic factors, the percentage of intratumoral lymphocytes was a significant independent parameter for pathologic complete response (pCR) in both cohorts (training cohort: P = .012; validation cohort: P = .001). Lymphocyte-predominant breast cancer responded, with pCR rates of 42% (training cohort) and 40% (validation cohort). In contrast, those tumors without any infiltrating lymphocytes had pCR rates of 3% (training cohort) and 7% (validation cohort). The expression of inflammatory marker genes and proteins was linked to the histopathologic infiltrate, and logistic regression showed a significant association of the T-cell–related markers CD3D and CXCL9 with pCR. Conclusion: The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Self-citationTempleton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Self-citationLoi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Self-citationKeren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183
“Several studies have shown increased tumor infiltrating lymphocytes (TILs) in TNBC compared to other breast cancers and correlations between specific immune subsets and prognosis (Andre et al., 2013; Denkert et al., 2010; Disis and Stanton, 2015; Teng et al., 2015), leading to clinical studies of several immunotherape…”
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., Ravoet, M., Le Buanec, H., Sibille, C., Manfouo-Foutsop, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67428 · Cited by 1,070
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Self-citationKathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Self-citationTargeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32454-0 · Cited by 872
Self-citationZitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3886 · Cited by 816
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialHendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Self-citationCancer classification using the Immunoscore: a worldwide task force
Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 791
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Templeton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 709
Self-citationMa, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Ectopic lymphoid-like structures in infection, cancer and autoimmunity
Pitzalis, C., Jones, G. W., Bombardieri, M., & Jones, S. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3700 · Cited by 698
Immune parameters affecting the efficacy of chemotherapeutic regimens
Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 669
Multi-omic machine learning predictor of breast cancer therapy response
Sammut, S.-J., Crispin-Ortuzar, M., Chin, S.-F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S.-J., Abraham, J. E., et al. (2022) · Nature · doi:10.1038/s41586-021-04278-5 · Cited by 654
Stanton, S. E., Adams, S., & Disis, M. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1061 · Cited by 631
Ali, H. R., Chlon, L., Pharoah, P. D. P., Markowetz, F., & Caldas, C. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002194 · Cited by 615
Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605
Self-citationLi, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., O’Regan, R., Torres, M. A., & Meisel, J. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4059-6 · Cited by 540
Martinet, L., Garrido, I., Filleron, T., Le Guellec, S., Bellard, E., Fournie, J.-J., Rochaix, P., & Girard, J.-P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 516
Prognostic and predictive value of PDL1 expression in breast cancer
Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3216 · Cited by 508
Leukocyte composition of human breast cancer
Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 479
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 453
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy
Williams, C. B., Yeh, E. S., & Soloff, A. C. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2015.25 · Cited by 444
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Ulloa-Montoya, F., Louahed, J., Dizier, B., Gruselle, O., Spiessens, B., Lehmann, F. F., Suciu, S., Kruit, W. H. J., Eggermont, A. M. M., Vansteenkiste, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3762 · Cited by 436
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Self-citationMIBI-TOF: A multiplexed imaging platform relates cellular phenotypes and tissue structure
Keren, L., Bosse, M., Thompson, S., Risom, T., Vijayaragavan, K., McCaffrey, E., Marquez, D., Angoshtari, R., Greenwald, N. F., Fienberg, H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax5851 · Cited by 431
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.004 · Cited by 396
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 387
Triple-negative breast cancer: treatment challenges and solutions
Jerusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s69488 · Cited by 385
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Bense, R. D., Sotiriou, C., Piccart-Gebhart, M. J., Haanen, J. B. A. G., van Vugt, M. A. T. M., de Vries, E. G. E., Schröder, C. P., & Fehrmann, R. S. N. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw192 · Cited by 379
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00069 · Cited by 365
West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 356
Immunological differences between primary and metastatic breast cancer
Szekely, B., Bossuyt, V., Li, X., Wali, V. B., Patwardhan, G. A., Frederick, C., Silber, A., Park, T., Harigopal, M., Pelekanou, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy399 · Cited by 354
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma
Nguyen, N., Bellile, E., Thomas, D., McHugh, J., Rozek, L., Virani, S., Peterson, L., Carey, T. E., Walline, H., Moyer, J., et al. (2016) · Head & Neck · doi:10.1002/hed.24406 · Cited by 353
Xiao, Y., Ma, D., Zhao, S., Suo, C., Shi, J., Xue, M.-Z., Ruan, M., Wang, H., Zhao, J., Li, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3524 · Cited by 352
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129641 · Cited by 347
Spatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhaeberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3035 · Cited by 338
Self-citationCimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 335
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
The neutrophil-to-lymphocyte ratio: a narrative review
Socorro Faria, S., Fernandes Jr, P. C., Barbosa Silva, M. J., Lima, V. C., Fontes, W., Freitas-Junior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 332
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.634 · Cited by 317
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 315
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
Dieci, M. V., Mathieu, M. C., Guarneri, V., Conte, P., Delaloge, S., Andre, F., & Goubar, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv239 · Cited by 310
Natural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 310
Balermpas, P., Michel, Y., Wagenblast, J., Seitz, O., Weiss, C., Rödel, F., Rödel, C., & Fokas, E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.640 · Cited by 309
Ono, M., Tsuda, H., Shimizu, C., Yamamoto, S., Shibata, T., Yamamoto, H., Hirata, T., Yonemori, K., Ando, M., Tamura, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1554-7 · Cited by 308
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Choi, W., Czerniak, B., Ochoa, A., Su, X., Siefker-Radtke, A., Dinney, C., & McConkey, D. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.129 · Cited by 302
Yin, Y., Yao, S., Hu, Y., Feng, Y., Li, M., Bian, Z., Zhang, J., Qin, Y., Qi, X., Zhou, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1283 · Cited by 296
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
Mechanisms of immune evasion in breast cancer
Bates, J. P., Derakhshandeh, R., Jones, L., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 291
A gene expression signature identifies two prognostic subgroups of basal breast cancer
Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., Tallet, A., Chabannon, C., Extra, J.-M., Jacquemier, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0897-9 · Cited by 290
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 286
Denkert, C., Wienert, S., Poterie, A., Loibl, S., Budczies, J., Badve, S., Bago-Horvath, Z., Bane, A., Bedri, S., Brock, J., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.109 · Cited by 285
Self-citationCastells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Luen, S. J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., Kiermaier, A., Swain, S. M., Baselga, J., Michiels, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 278
The genomic landscape of breast cancer and its interaction with host immunity
Luen, S., Virassamy, B., Savas, P., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 277
Mao, Y., Qu, Q., Chen, X., Huang, O., Wu, J., & Shen, K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152500 · Cited by 275
Bronger, H., Singer, J., Windmüller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.172 · Cited by 274
Triple negative breast cancer: A thorough review of biomarkers
da Silva, J. L., Cardoso Nunes, N. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102855 · Cited by 270
Metadata
- Authors
- Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., von Törne, C., Weichert, W., Engels, K., Solbach, C., Schrader, I., Dietel, M., & von Minckwitz, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 105-113
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157058802
- Cited by
- 1,762
- References
- 34
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.